Comparison of Liver Safety of Favipiravir and Hydroxychloroquine in COVID-19 Treatment
| Autor: | Orhan Yildiz, Hatice Karagoz, Feyza Izci-Cetinkaya |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hydroxychloroquine Favipiravir Liver tests World health Infectious Diseases Pandemic medicine Intensive care medicine business medicine.drug |
| Zdroj: | Klimik Dergisi/Klimik Journal. 33:235-240 |
| ISSN: | 1309-1484 1301-143X |
| DOI: | 10.5152/kd.2020.49 |
| Popis: | Objective: Since the first case from Wuhan, China in December 2019, COVID-19 has spread all over the world and a pandemic was declared by the World Health Organization on January 30, 2020. While there are no specific effective antiviral drugs or vaccines to treat or to prevent COVID-19; favipiravir, hydroxy-chloroquine and their combination are used in the treatment of COVID-19 in Turkey. In this study, it was aimed to evaluate the demographic, clinical and laboratory findings, the treatments given and the effects of treatments on liver tests of the patients followed up with the diagnosis of COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|